Zacks Investment Ideas feature highlights: Boston Scientific, Meta Platforms and Microsoft
Werte in diesem Artikel
For Immediate ReleaseChicago, IL – May 2, 2025 – Today, Zacks Investment Ideas feature highlights Boston Scientific BSX, Meta Platforms META and Microsoft MSFT.These 3 Stocks Soared Following Quarterly ResultsThe 2025 Q1 earnings cycle is in full swing, with many companies on the docket to reveal quarterly results in the coming weeks.Guidance is a key factor in this cycle, more so than we’ve seen in recent periods due to the overall level of uncertainty brought about by recent tariff announcements and other economic developments.So far, several companies, including Boston Scientific, Meta Platforms and Microsoft, have all delivered positive results, with each seeing a bullish share reaction post-earnings. Let’s take a closer look at the positivity.BSX Raises GuidanceBoston Scientific exceeded both top and bottom line expectations handily, delivering a strong 12% EPS beat alongside sales that were 2.3% ahead of expectations. Upgraded current-year guidance has provided a notably bullish outlook, with the stock also now sporting a coveted Zacks Rank #2 (Buy).Analysts have adjusted their current year sales and EPS expectations accordingly following the favorable print, with BSX expected to see 16% EPS growth on 17% higher sales. The stock sports a Style Score of ‘B’ for Value.Strong segment performance has aided the company’s bright outlook, leading to the above-mentioned guidance upgrade in an overall uncertain environment.Meta Ad Revenue Remains RobustMeta Platforms continued to fire on all cylinders throughout its latest period, again exceeding our consensus EPS and sales expectations handily and posting strong growth. Sales grew an impressive 16% year-over-year thanks to strong Advertising results, which totaled a solid $41.3 billion.Notably, the company’s average price per ad climbed 10% year-over-year, with its family daily active people (DAP) also seeing a 6% move higher year-over-year. The company’s user base growth has continued to be outstanding, providing many clear benefits.Microsoft Cloud ImpressesConcerning headline figures in Microsoft’s release, EPS of $3.46 and sales of $70.0 billion both handily exceeded our consensus expectations, continuing its recent streak of better-than-expected results. Sales grew an impressive 13% year-over-year, whereas EPS climbed 18%.Unsurprisingly, Microsoft Cloud and AI strength drove the strong results, with Microsoft Cloud revenue soaring 20% year-over-year to $42.4 billion. Demand has remained strong for the tech titan, with commentary alluding to the trend remaining for years to come.Importantly, its Intelligent Cloud (includes Azure) revenue totaled a strong $26.8 billion, up 21% from the year-ago period. The Intelligent Cloud results snapped a small streak of misses on the metric.Bottom LineThe 2025 Q1 cycle continues to roll along, with all three stocks above seeing a nice move higher following their respective quarterly releases.Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Boston Scientific und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Boston Scientific
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Microsoft Corp.
Analysen zu Microsoft Corp.
Datum | Rating | Analyst | |
---|---|---|---|
01.05.2025 | Microsoft Buy | UBS AG | |
01.05.2025 | Microsoft Overweight | JP Morgan Chase & Co. | |
01.05.2025 | Microsoft Buy | Jefferies & Company Inc. | |
01.05.2025 | Microsoft Outperform | RBC Capital Markets | |
28.04.2025 | Microsoft Buy | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
01.05.2025 | Microsoft Buy | UBS AG | |
01.05.2025 | Microsoft Overweight | JP Morgan Chase & Co. | |
01.05.2025 | Microsoft Buy | Jefferies & Company Inc. | |
01.05.2025 | Microsoft Outperform | RBC Capital Markets | |
28.04.2025 | Microsoft Buy | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
31.05.2023 | Microsoft Neutral | UBS AG | |
27.04.2023 | Microsoft Neutral | UBS AG | |
20.04.2023 | Microsoft Neutral | UBS AG | |
17.03.2023 | Microsoft Neutral | UBS AG | |
14.03.2023 | Microsoft Neutral | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
03.07.2020 | Microsoft verkaufen | Credit Suisse Group | |
19.11.2018 | Microsoft Underperform | Jefferies & Company Inc. | |
26.09.2018 | Microsoft Underperform | Jefferies & Company Inc. | |
14.06.2018 | Microsoft Underperform | Jefferies & Company Inc. | |
13.06.2018 | Microsoft Underperform | Jefferies & Company Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Microsoft Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen